Bioequivalence of linagliptin 5 mg once daily and 25 mg twice daily: Pharmacokinetics and pharmacodynamics in an open-label crossover trial

Drug Research

Volumn 64, Issue 5, 2014, Pages 269-275

  Friedrich, C ^a   Jungnik, A ^a   Retlich, S ^a   Ring, A ^a   Meinicke, T ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

diabetes; fixed dose combination; linagliptin; metformin; pharmacodynamics; pharmacokinetics

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; LINAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; EVENING DOSAGE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HERPETIC STOMATITIS; HUMAN; HUMAN EXPERIMENT; MALE; MORNING DOSAGE; NORMAL HUMAN; PRURITUS; RHINOPHARYNGITIS; SIMULATION; SKIN INJURY; STEADY STATE; ADOLESCENT; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; THERAPEUTIC EQUIVALENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; CROSS-OVER STUDIES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PURINES; QUINAZOLINES; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84899947620     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0033-1357144     Document Type: Article

References (26)

1. American Diabetes Association Standards of medical care in diabetes - 2012. Diabetes Care: 2012; 35 01 S11 S63
2. Stratton I. M., Adler A. I., Neil H. A. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ: 2000; 321 405 412 (Pubitemid 30609442)
3. Freeman M. K. Efficacy and safety of linagliptin (Tradjenta) in adults with type-2 diabetes mellitus. P T: 2011; 36 807 842
4. Del Prato S., Barnett A. H., Huisman H. et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab: 2011; 13 258 267
5. McGill J. B. Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials. Ther Adv Endocrinol Metab: 2012; 3 113 124
6. Inzucchi S. E., Bergenstal R. M., Buse J. B. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care: 2012; 35 1364 1379
7. DeFronzo R. A., Barzilai N., Simonson D. C. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab: 1991; 73 1294 1301 (Pubitemid 121000706)
8. Taskinen M. R., Rosenstock J., Tamminen I. et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab: 2011; 13 65 74
9. Haak T., Meinicke T., Jones R. et al. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab: 2012; 14 565 574
10. Forst T., Uhlig-Laske B., Ring A. et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med: 2010; 27 1409 1419
11. Gallwitz B., Rosenstock J., Rauch T. et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet: 2012; 380 475 483
12. Han S., Iglay K., Davies M. J. et al. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin: 2012; 28 969 977
13. Boehringer Ingelheim Tradjenta (linagliptin). US Prescribing Information, September: 2012
14. Bristol-Myers Squibb GLUCOPHAGE® (metformin hydrochloride) Tablets, January: 2009
15. Graefe-Mody U., Retlich S., Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet: 2012; 51 411 427
16. Retlich S., Duval V., Graefe-Mody U. et al. Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J Clin Pharmacol: 2010; 50 873 885
17. Fuchs H., Tillement J. P., Urien S. et al. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol: 2009; 61 55 62
18. Heise T., Graefe-Mody E. U., Hüttner S. et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab: 2009; 11 786 794
19. Forst T., Uhlig-Laske B., Ring A. et al. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab: 2011; 13 542 550
20. Hoffman D., Kringle R., Lockwood G. et al. Nonlinear mixed effects modelling for estimation of steady state attainment. Pharmaceutical Statistics: 2005; 4 15 24 (Pubitemid 40425992)
21. th Konferenz der SAS Anwender in Forschung und Entwicklung (KSFE; Conference of SAS users in research and development), Martin-Luther-University Halle-Wittenberg, Halle, Germany; March 5-6, 2009. http://www.ksfe2009.uni-halle.de/abstracts/Weyhmueller.pdf?Donnerstag,%205. %20M%E4rz%202009%2011:30,%A0%A0HS%20XXIII (Accessed December 7, 2012) (German)
22. Schernthaner G., Barnett A. H., Emser A. et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab: 2012; 14 470 478
23. Ross S. A., Rafeiro E., Meinicke T. et al. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin: 2012; 28 1465 1474
24. Buschke S., Ring A., Friedrich C. et al. Linagliptin fixed-dose combination with metformin is bioequivalent to loose-pill combination therapy (Presented at the American College of Clinical Pharmacy - Annual Meeting, Hollywood, FL; Oct 21-24, 2012; abstract #208). Pharmacotherapy: 2012; 32 e238
25. Boehringer Ingelheim Jentadueto™ (linagliptin and metformin hydrochloride) tablets prescribing information 2012. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/201281s000lbl.pdf (Accessed May 23, 2013)
26. Boehringer Ingelheim Jentadueto SUMMARY OF PRODUCT CHARACTERISTICS. 2012. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002279/WC500130969.pdf (Accessed February 8, 2013)